{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:14:50Z","timestamp":1790255690441,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Jiangxi Provincial Health Technology Project","award":["202410465;202410446"],"award-info":[{"award-number":["202410465;202410446"]}]},{"name":"Science and Technology Program of Jiangxi Administration of Traditional Chinese Medicine","award":["2023B1269"],"award-info":[{"award-number":["2023B1269"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82260570"],"award-info":[{"award-number":["82260570"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science Technology Foundation of Jiangxi Province","award":["20224BAB216056"],"award-info":[{"award-number":["20224BAB216056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00280-024-04704-1","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T16:55:42Z","timestamp":1722876942000},"page":"669-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Selinexor targeting XPO1 promotes PEG3 nuclear accumulation and suppresses cholangiocarcinoma progression"],"prefix":"10.1007","volume":"94","author":[{"given":"Deng","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongshan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linquan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"4704_CR1","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA (2022) Current epidemiology of cholangiocarcinoma in western countries. J Hepatol 77:1690\u20131698. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.022","journal-title":"J Hepatol"},{"key":"4704_CR2","doi-asserted-by":"publisher","unstructured":"Khan SA, Tavolari S, Brandi G (2019) Cholangiocarcinoma: epidemiology and risk factors. Liver Int 39 Suppl 119\u201331. https:\/\/doi.org\/10.1111\/liv.14095","DOI":"10.1111\/liv.14095"},{"key":"4704_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.32074\/1591-951X-252","volume":"113","author":"S Sarcognato","year":"2021","unstructured":"Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M (2021) Cholangiocarcinoma Pathologica 113:158\u2013169. https:\/\/doi.org\/10.32074\/1591-951X-252","journal-title":"Cholangiocarcinoma Pathologica"},{"key":"4704_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME (2023) Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin 73:198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759","journal-title":"CA Cancer J Clin"},{"key":"4704_CR5","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1177\/10781552231171079","volume":"29","author":"E Lodl","year":"2023","unstructured":"Lodl E, Ramnaraign B, Sahin I, Wheeler S (2023) Updates in the use of targeted therapies for the treatment of cholangiocarcinoma. J Oncol Pharm Pract 29:1206\u20131217. https:\/\/doi.org\/10.1177\/10781552231171079","journal-title":"J Oncol Pharm Pract"},{"key":"4704_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/14656566.2021.2020250","volume":"23","author":"G Spolverato","year":"2022","unstructured":"Spolverato G, Glavas D, Hewitt DB, Brown ZJ, Capelli G, Bergamo F, Rizzato MD, Pawlik TM (2022) Advances in pharmacotherapy for cholangiocarcinoma: from conventional therapies to targeted drugs. Expert Opin Pharmacother 23:473\u2013481. https:\/\/doi.org\/10.1080\/14656566.2021.2020250","journal-title":"Expert Opin Pharmacother"},{"key":"4704_CR7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, Gores GJ (2023) Cholangiocarcinoma - novel biological insights and therapeutic strategies. Nat Rev Clin Oncol 20:470\u2013486. https:\/\/doi.org\/10.1038\/s41571-023-00770-1","journal-title":"Nat Rev Clin Oncol"},{"key":"4704_CR8","doi-asserted-by":"publisher","first-page":"e1010003","DOI":"10.1371\/journal.pgen.1010003","volume":"18","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, Besson V, Rivagorda M, Oury F, Marazzi G, Sassoon DA (2022) Paternally expressed gene 3 (Pw1\/Peg3) promotes sexual dimorphism in metabolism and behavior. PLoS Genet 18:e1010003. https:\/\/doi.org\/10.1371\/journal.pgen.1010003","journal-title":"PLoS Genet"},{"key":"4704_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.5808\/GI.2014.12.3.105","volume":"12","author":"H He","year":"2014","unstructured":"He H, Kim J (2014) Regulation and function of the peg3 imprinted domain. Genomics Inf 12:105\u2013113. https:\/\/doi.org\/10.5808\/GI.2014.12.3.105","journal-title":"Genomics Inf"},{"key":"4704_CR10","doi-asserted-by":"publisher","first-page":"e975645","DOI":"10.4161\/23723556.2014.975645","volume":"2","author":"T Neill","year":"2015","unstructured":"Neill T, Schaefer L, Iozzo RV (2015) Oncosuppressive functions of decorin. Mol Cell Oncol 2:e975645. https:\/\/doi.org\/10.4161\/23723556.2014.975645","journal-title":"Mol Cell Oncol"},{"key":"4704_CR11","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.gene.2012.10.005","volume":"512","author":"MM Thiaville","year":"2013","unstructured":"Thiaville MM, Huang JM, Kim H, Ekram MB, Tae-Young Roh JK (2013) DNA-binding motif and target genes of the imprinted transcription factor PEG3. Gene 512:314\u2013320. https:\/\/doi.org\/10.1016\/j.gene.2012.10.005","journal-title":"Gene"},{"key":"4704_CR12","unstructured":"Uhl\u00e9n M, Fagerberg L, Hallstr\u00f6m B (2023) The human protein atlas: https:\/\/www.proteinatlas.org\/ENSG00000198300-PEG3\/tissue#expression_summary. The human protein atlas"},{"key":"4704_CR13","doi-asserted-by":"publisher","first-page":"100789","DOI":"10.1016\/j.currproblcancer.2021.100789","volume":"46","author":"H Hashmi","year":"2022","unstructured":"Hashmi H, Green K (2022) The \u2018comeback\u2019 of Selinexor: from toxic to tolerable. Curr Probl Cancer 46:100789. https:\/\/doi.org\/10.1016\/j.currproblcancer.2021.100789","journal-title":"Curr Probl Cancer"},{"key":"4704_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-023-01649-4","volume":"8","author":"Y Yang","year":"2023","unstructured":"Yang Y, Guo L, Chen L, Gong B, Jia D, Sun Q (2023) Nuclear transport proteins: structure, function, and disease relevance. Signal Transduct Target Ther 8:425. https:\/\/doi.org\/10.1038\/s41392-023-01649-4","journal-title":"Signal Transduct Target Ther"},{"key":"4704_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41571-020-00442-4","volume":"18","author":"AS Azmi","year":"2021","unstructured":"Azmi AS, Uddin MH, Mohammad RM (2021) The nuclear export protein XPO1 - from biology to targeted therapy. Nat Rev Clin Oncol 18:152\u2013169. https:\/\/doi.org\/10.1038\/s41571-020-00442-4","journal-title":"Nat Rev Clin Oncol"},{"key":"4704_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/jha2.709","volume":"4","author":"CC Mo","year":"2023","unstructured":"Mo CC, Yee AJ, Midha S, Hartley-Brown MA, Nadeem O, O\u2019Donnell EK, Bianchi G, Sperling AS, Laubach JP, Richardson PG (2023) Selinexor: targeting a novel pathway in multiple myeloma. EJHaem 4:792\u2013810. https:\/\/doi.org\/10.1002\/jha2.709","journal-title":"EJHaem"},{"key":"4704_CR17","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00432-022-04247-z","volume":"149","author":"JR Landes","year":"2023","unstructured":"Landes JR, Moore SA, Bartley BR, Doan HQ, Rady PL, Tyring SK (2023) The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. J Cancer Res Clin Oncol 149:2139\u20132155. https:\/\/doi.org\/10.1007\/s00432-022-04247-z","journal-title":"J Cancer Res Clin Oncol"},{"key":"4704_CR18","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17474086.2022.2057295","volume":"15","author":"C Sylvain","year":"2022","unstructured":"Sylvain C (2022) A drug profile on selinexor for the treatment of refractory diffuse large B-cell lymphoma. Expert Rev Hematol 15:195\u2013201. https:\/\/doi.org\/10.1080\/17474086.2022.2057295","journal-title":"Expert Rev Hematol"},{"key":"4704_CR19","doi-asserted-by":"publisher","first-page":"5751","DOI":"10.1002\/cam4.5322","volume":"12","author":"C Zhao","year":"2023","unstructured":"Zhao C, Ma B, Yang Z-Y, Li O, Liu S-L, Pan L-J, Gong W, Dong P, Shu Y-J (2023) Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation. Cancer Med 12:5751\u20135763. https:\/\/doi.org\/10.1002\/cam4.5322","journal-title":"Cancer Med"},{"key":"4704_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y (2023) Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther 8:160. https:\/\/doi.org\/10.1038\/s41392-023-01419-2","journal-title":"Signal Transduct Target Ther"},{"key":"4704_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12935-022-02454-9","volume":"22","author":"B Pan","year":"2022","unstructured":"Pan B, Wei X, Xu X (2022) Patient-derived xenograft models in hepatopancreatobiliary cancer. Cancer Cell Int 22:41. https:\/\/doi.org\/10.1186\/s12935-022-02454-9","journal-title":"Cancer Cell Int"},{"key":"4704_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/15384101.2017.1314406","volume":"16","author":"K Kawaguchi","year":"2017","unstructured":"Kawaguchi K, Igarashi K, Murakami T, Kiyuna T, Nelson SD, Dry SM, Li Y, Russell TA, Singh AS, Chmielowski B, Unno M, Eilber FC, Hoffman RM (2017) Combination of gemcitabine and docetaxel regress both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. Cell Cycle 16:1063\u20131069. https:\/\/doi.org\/10.1080\/15384101.2017.1314406","journal-title":"Cell Cycle"},{"key":"4704_CR23","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.3390\/cancers12092397","volume":"12","author":"EK Cotul","year":"2020","unstructured":"Cotul EK, Zuo Q, Santaliz-Casiano A, Imir OB, Mogol AN et al (2020) Combined targeting of Estrogen Receptor Alpha and Exportin 1 in metastatic breast cancers. Cancers (Basel) 12:2397. https:\/\/doi.org\/10.3390\/cancers12092397","journal-title":"Cancers (Basel)"},{"key":"4704_CR24","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.2147\/OTT.S208060","volume":"12","author":"T Zhou","year":"2019","unstructured":"Zhou T, Lin W, Zhu Q, Renaud H, Liu X, Li R, Tang C, Ma C, Rao T, Tan Z, Guo Y (2019) The role of PEG3 in the occurrence and prognosis of colon cancer. Onco Targets Ther 12:6001\u20136012. https:\/\/doi.org\/10.2147\/OTT.S208060","journal-title":"Onco Targets Ther"},{"key":"4704_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/CAD.0000000000001288","volume":"33","author":"W Fang","year":"2022","unstructured":"Fang W, Xia Y (2022) LncRNA HLA-F-AS1 attenuates the ovarian cancer development by targeting miR-21-3p\/PEG3 axis. Anticancer Drugs 33:671\u2013681. https:\/\/doi.org\/10.1097\/CAD.0000000000001288","journal-title":"Anticancer Drugs"},{"key":"4704_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1007\/s43032-022-01053-3","volume":"30","author":"J Wang","year":"2023","unstructured":"Wang J, Chen X, Zheng L, Ding C, Ma X (2023) Circ_0042986 Presence restrains cervical Cancer Development via Upregulating PEG3 by directly targeting miR-582-3p. Reprod Sci 30:890\u2013902. https:\/\/doi.org\/10.1007\/s43032-022-01053-3","journal-title":"Reprod Sci"},{"key":"4704_CR27","doi-asserted-by":"publisher","first-page":"110662","DOI":"10.1016\/j.cellsig.2023.110662","volume":"107","author":"T Qiu","year":"2023","unstructured":"Qiu T, Ding Y, Qin J, Ren D, Xie M, Qian Q, Wang Y, Ma L, Jing A, Yang J, Ma S, Wang X, Wang W, Ji J, Li G (2023) Epigenetic reactivation of PEG3 by EZH2 inhibitors suppresses renal clear cell carcinoma progress. Cell Signal 107:110662. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110662","journal-title":"Cell Signal"},{"key":"4704_CR28","doi-asserted-by":"publisher","first-page":"7903","DOI":"10.7150\/thno.76873","volume":"12","author":"Y-D Luo","year":"2022","unstructured":"Luo Y-D, Liu X-Y, Fang L, Yu H-Q, Zhang Y-J, Chen M, Zhang L-D, Xie C-M (2022) Mutant Kras and mTOR crosstalk drives hepatocellular carcinoma development via PEG3\/STAT3\/BEX2 signaling. Theranostics 12:7903\u20137919. https:\/\/doi.org\/10.7150\/thno.76873","journal-title":"Theranostics"},{"key":"4704_CR29","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1073\/pnas.040378897","volume":"97","author":"F Relaix","year":"2000","unstructured":"Relaix F, Wei Xj, Li W, Pan J, Lin Y, Bowtell DD, Sassoon DA, Wu X (2000) Pw1\/Peg3 is a potential cell death mediator and cooperates with Siah1a in p53-mediated apoptosis. Proc Natl Acad Sci U S A 97:2105\u20132110. https:\/\/doi.org\/10.1073\/pnas.040378897","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4704_CR30","doi-asserted-by":"publisher","first-page":"8472","DOI":"10.1074\/jbc.M109.069450","volume":"285","author":"X Jiang","year":"2010","unstructured":"Jiang X, Yu Y, Yang HW, Agar NYR, Frado L, Johnson MD (2010) The imprinted gene PEG3 inhibits wnt signaling and regulates glioma growth. J Biol Chem 285:8472\u20138480. https:\/\/doi.org\/10.1074\/jbc.M109.069450","journal-title":"J Biol Chem"},{"key":"4704_CR31","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-014-0078-0","volume":"7","author":"K Parikh","year":"2014","unstructured":"Parikh K, Cang S, Sekhri A, Liu D (2014) Selective inhibitors of nuclear export (sine)\u2014A novel class of anti-cancer agents. J Hematol Oncol 7:78. https:\/\/doi.org\/10.1186\/s13045-014-0078-0","journal-title":"J Hematol Oncol"},{"key":"4704_CR32","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.drudis.2020.06.014","volume":"25","author":"MH Uddin","year":"2020","unstructured":"Uddin MH, Zonder JA, Azmi AS (2020) Exportin 1 inhibition as antiviral therapy. Drug Discov Today 25:1775\u20131781. https:\/\/doi.org\/10.1016\/j.drudis.2020.06.014","journal-title":"Drug Discov Today"},{"key":"4704_CR33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","volume":"4","author":"DSP Tan","year":"2014","unstructured":"Tan DSP, Bedard PL, Kuruvilla J, Siu LL, Razak ARA (2014) Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy. Cancer Discov 4:527\u2013537. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-1005","journal-title":"Cancer Discov"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04704-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04704-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04704-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T17:02:10Z","timestamp":1728752530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04704-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["4704"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04704-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"23 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}